These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 20021203)

  • 1. Neurosurgeons achieve world's first delivery of intra-arterial bevacizumab directly into brain tumor of glioblastoma multiforme patients.
    Future Oncol; 2010 Jan; 6(1):9. PubMed ID: 20021203
    [No Abstract]   [Full Text] [Related]  

  • 2. World's first delivery of intra-arterial bevacizumab directly into brain tumor of glioblastoma multiforme patients.
    Expert Rev Anticancer Ther; 2010 Jan; 10(1):5. PubMed ID: 20014880
    [No Abstract]   [Full Text] [Related]  

  • 3. Superselective intra-arterial cerebral infusion of novel agents after blood-brain disruption for the treatment of recurrent glioblastoma multiforme: a technical case series.
    Shin BJ; Burkhardt JK; Riina HA; Boockvar JA
    Neurosurg Clin N Am; 2012 Apr; 23(2):323-9, ix-x. PubMed ID: 22440875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Orthotopic glioblastoma stem-like cell xenograft model in mice to evaluate intra-arterial delivery of bevacizumab: from bedside to bench.
    Burkhardt JK; Hofstetter CP; Santillan A; Shin BJ; Foley CP; Ballon DJ; Pierre Gobin Y; Boockvar JA
    J Clin Neurosci; 2012 Nov; 19(11):1568-72. PubMed ID: 22985932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Superselective intraarterial cerebral infusion of bevacizumab: a revival of interventional neuro-oncology for malignant glioma.
    Riina HA; Fraser JF; Fralin S; Knopman J; Scheff RJ; Boockvar JA
    J Exp Ther Oncol; 2009; 8(2):145-50. PubMed ID: 20192120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluorescence-guided operation in recurrent glioblastoma multiforme treated with bevacizumab-fluorescence of the noncontrast enhancing tumor tissue?
    Wachter D; Kallenberg K; Wrede A; Schulz-Schaeffer W; Behm T; Rohde V
    J Neurol Surg A Cent Eur Neurosurg; 2012 Nov; 73(6):401-6. PubMed ID: 22777926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bevacizumab-induced diffusion restriction in patients with glioma: tumor progression or surrogate marker of hypoxia?
    Rieger J; Bähr O; Ronellenfitsch MW; Steinbach J; Hattingen E
    J Clin Oncol; 2010 Sep; 28(27):e477; author reply e478. PubMed ID: 20585096
    [No Abstract]   [Full Text] [Related]  

  • 8. Bevacizumab and recurrent malignant gliomas: a European perspective.
    Wick W; Weller M; van den Bent M; Stupp R
    J Clin Oncol; 2010 Apr; 28(12):e188-9; author reply e190-2. PubMed ID: 20159801
    [No Abstract]   [Full Text] [Related]  

  • 9. Cost analysis of intra-arterial versus intra-venous delivery of bevacizumab for the treatment of recurrent glioblastoma multiforme.
    Burkhardt JK; Shin BJ; Schlaff CD; Riina H; Boockvar JA
    J Exp Ther Oncol; 2011; 9(3):183-6. PubMed ID: 22070049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [MR imaging for accurate response monitoring in glioblastoma multiforme during bevacizumab therapy].
    Korn A; Braun C; Fenchel M; Ernemann U; Horger M
    Rofo; 2012 May; 184(5):397-401. PubMed ID: 22576602
    [No Abstract]   [Full Text] [Related]  

  • 11. Optic neuropathy in patients with glioblastoma receiving bevacizumab.
    Chamberlain MC; Raizer J; Schiff D; Sherman JH
    Neurology; 2010 Jul; 75(3):289-90; author reply 290. PubMed ID: 20644159
    [No Abstract]   [Full Text] [Related]  

  • 12. Ocular and orbital complications of intraarterial cisplatin. A case report.
    Wu HM; Lee AG; Lehane DE; Chi TL; Lewis RA
    J Neuroophthalmol; 1997 Sep; 17(3):195-8. PubMed ID: 9304534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme.
    Cohen MH; Shen YL; Keegan P; Pazdur R
    Oncologist; 2009 Nov; 14(11):1131-8. PubMed ID: 19897538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of avastin in the management of recurrent glioblastoma.
    Sweet JA; Feinberg ML; Sherman JH
    Neurosurg Clin N Am; 2012 Apr; 23(2):331-41, x. PubMed ID: 22440876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enigma of a rapid introduction of antiangiogenic therapy with bevacizumab in glioblastoma: a new era in the treatment of malignant brain tumours?
    Henriksson R; Bergström P; Johansson M; Sandström M
    Acta Oncol; 2009; 48(1):6-8. PubMed ID: 18932097
    [No Abstract]   [Full Text] [Related]  

  • 16. The role of bevacizumab in glioblastoma.
    Nabors LB
    J Natl Compr Canc Netw; 2014 Sep; 12(9):1201-2. PubMed ID: 25190689
    [No Abstract]   [Full Text] [Related]  

  • 17. A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas.
    Raizer JJ; Grimm S; Chamberlain MC; Nicholas MK; Chandler JP; Muro K; Dubner S; Rademaker AW; Renfrow J; Bredel M
    Cancer; 2010 Nov; 116(22):5297-305. PubMed ID: 20665891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrins as target: first phase III trial launches, but questions remain.
    Carter A
    J Natl Cancer Inst; 2010 May; 102(10):675-7. PubMed ID: 20460633
    [No Abstract]   [Full Text] [Related]  

  • 19. Molecular characteristics and pathways of Avastin for the treatment of glioblastoma multiforme.
    Spasic M; Chow F; Tu C; Nagasawa DT; Yang I
    Neurosurg Clin N Am; 2012 Jul; 23(3):417-27. PubMed ID: 22748654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intra-arterial bevacizumab with blood brain barrier disruption in a glioblastoma xenograft model.
    Burkhardt JK; Santillan A; Hofstetter CP; Christos P; Berry N; Shin BJ; Foley CP; Gürsel DB; Ballon DJ; Gobin YP; Boockvar JA
    J Exp Ther Oncol; 2012; 10(1):31-7. PubMed ID: 22946342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.